Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myelodysplastic Syndromes 26Leukemia, Myeloid, Acute 24Lymphoma, Non-Hodgkin 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Leukemia 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Hodgkin Disease 16Hematologic Neoplasms 16Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Multiple Myeloma 11Myeloproliferative Disorders 10Graft vs Host Disease 9Primary Myelofibrosis 8Leukemia, Myelomonocytic, Juvenile 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Myelomonocytic, Chronic 6Neoplasms 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia, Myeloid, Accelerated Phase 5Burkitt Lymphoma 5Anemia, Refractory, with Excess of Blasts 5Leukemia, Myeloid, Chronic-Phase 4Congenital Abnormalities 4Blast Crisis 4Waldenstrom Macroglobulinemia 3Neuroblastoma 3

Interventions

Cyclophosphamide 3fludarabine phosphate 2Whole-Body Irradiation 2Fentanyl 2thymoglobulin 1fludarabine 1Thiotepa 1Tacrolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Melphalan 1Medical Marijuana 1Dexamethasone 1Busulfan 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia, Sickle Cell × thymoglobulin × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡